The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Leadership - Sanomics
Stock and Other Ownership Interests - Sanomics
Honoraria - ACEA Biosciences; Amgen; AstraZeneca; Aveo/Biodesix; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Janssen-Ortho; Lilly; Merck; MSD; Novartis; Prime Oncology; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Consulting or Advisory Role - ACEA Biosciences; Amgen; AstraZeneca; Aveo/Biodesix; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Gene Decode; Janssen-Ortho; Lilly; Merck; MSD; Novartis; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Janssen-Ortho; Lilly; MSD; Novartis; Pfizer; Prime Oncology; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); SFJ Pharmaceuticals Group (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck; Novartis; Pfizer; Roche/Genentech
Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC.
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - Amgen; AstraZeneca; Biothera; Clovis Oncology; Genentech; Genentech; Gensignia Life Sciences; Janssen; Janssen; Lilly; Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); ITO - EN (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Federico Cappuzzo
Honoraria - Bristol-Myers Squibb; Clovis Oncology; Pfizer; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; Clovis Oncology; Lilly; Pfizer; Roche/Genentech
 
Robert M. Jotte
Honoraria - Bristol-Myers Squibb; Lilly
Speakers' Bureau - Bristol-Myers Squibb; Lilly
 
Martin Reck
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Pfizer; Roche/Genentech
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Pfizer; Roche/Genentech
 
Tony Mok
No Relationships to Disclose
 
Alan Sandler
Employment - Genentech/Roche
Stock and Other Ownership Interests - Roche
 
Daniel Waterkamp
Employment - Genentech
Stock and Other Ownership Interests - Genentech
 
Shelley Coleman
Employment - Genentech
Stock and Other Ownership Interests - Celgene; Gilead Sciences; Merck; Roche/Genentech; Teva
Travel, Accommodations, Expenses - Genentech
 
Yasuo Sugitani
Employment - Chugai Pharma; Genentech
 
Mark A. Socinski
Honoraria - Genentech
Consulting or Advisory Role - Genentech
Research Funding - Pfizer (Inst)